Abstract
Background: We investigated the association between N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) levels upon hospital admission and early hematoma growth (HG), inhospital pneumonia and major disability in patients with acute intracerebral hemorrhage (ICH).
Methods: A total of 353 ICH patients from January 2014 to February 2019 were included in the present study. Patients were divided into three groups based on the admission NT-proBNP levels (T1: <61; T2: 61-199; T3: ≥199 pg/mL). Logistic regression models were used to estimate the effect of NT-proBNP on early HG, in-hospital pneumonia, and major disability upon hospital discharge (modified Rankin Scale score ≥5) in ICH patients.
Results: There was no significant association observed between baseline NT-proBNP levels and early HG (P-trend =0.249). The risk of in-hospital pneumonia was significantly higher in patients with the highest NT-proBNP level (T3) (adjusted odds ratio [OR] 2.13; 95% confidence interval [CI], 1.11-4.08) and higher NT-proBNP level (T2) (adjusted OR 2.18; 95% CI, 1.19-4.00) compared to those with lowest NT-proBNP level (T1). The highest NT-proBNP level (T3) was associated with a 3.55-fold increase in the risk of major disability at hospital discharge (adjusted OR 3.55; 95% CI, 1.23-10.26; P-trend =0.013) in comparison to T1 after adjustment for potential covariates, including pneumonia.
Conclusion: Increased NT-proBNP at admission was independently associated with in-hospital pneumonia and major disability upon discharge but not early hematoma growth in acute ICH patients.
[http://dx.doi.org/10.1016/S2214-109X(20)30069-3] [PMID: 32199124]
[http://dx.doi.org/10.1016/S1474-4422(09)70025-0] [PMID: 19233729]
[http://dx.doi.org/10.1177/1747493018806196] [PMID: 30346258]
[http://dx.doi.org/10.1212/WNL.0b013e3182143317] [PMID: 21346218]
[http://dx.doi.org/10.1056/NEJMcibr1204796] [PMID: 22830469]
[http://dx.doi.org/10.1056/NEJM199807303390507] [PMID: 9682046]
[http://dx.doi.org/10.1161/01.STR.0000162751.54349.ae] [PMID: 15802631]
[http://dx.doi.org/10.1161/JAHA.120.017499] [PMID: 32875935]
[http://dx.doi.org/10.1016/j.clineuro.2021.107021] [PMID: 34808477]
[http://dx.doi.org/10.2169/internalmedicine.48.2166] [PMID: 19755761]
[http://dx.doi.org/10.1161/STROKEAHA.111.634089] [PMID: 22020034]
[http://dx.doi.org/10.1212/WNL.0000000000000634] [PMID: 25024445]
[http://dx.doi.org/10.3389/fneur.2021.775085] [PMID: 34867764]
[http://dx.doi.org/10.1016/j.jns.2019.02.014] [PMID: 30772761]
[http://dx.doi.org/10.1159/000356198] [PMID: 24457596]
[http://dx.doi.org/10.1016/j.ijcard.2007.03.108] [PMID: 17477984]
[http://dx.doi.org/10.1016/j.ijcard.2013.12.119] [PMID: 24433615]
[http://dx.doi.org/10.1111/j.1365-2796.2005.01540.x] [PMID: 16164581]
[http://dx.doi.org/10.1161/01.STR.27.8.1304] [PMID: 8711791]
[http://dx.doi.org/10.1016/S0196-6553(89)80013-6] [PMID: 2538096]
[http://dx.doi.org/10.1016/j.ijcard.2014.07.001] [PMID: 25049007]
[http://dx.doi.org/10.1161/01.CIR.0000046777.74753.F8] [PMID: 12515766]
[http://dx.doi.org/10.1056/NEJMoa011053] [PMID: 11586953]
[http://dx.doi.org/10.1056/NEJMoa031994] [PMID: 14960742]
[http://dx.doi.org/10.1007/s00415-017-8602-0] [PMID: 28840579]
[http://dx.doi.org/10.1016/j.cyto.2018.07.037] [PMID: 30098475]
[http://dx.doi.org/10.1097/NRL.0000000000000269] [PMID: 32358460]
[http://dx.doi.org/10.1016/j.ejim.2012.03.015] [PMID: 22863434]
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2019.02.030] [PMID: 30930241]
[http://dx.doi.org/10.1016/S1474-4422(20)30364-1] [PMID: 33212054]
[http://dx.doi.org/10.1093/brain/awz393] [PMID: 31919518]